|
SCOLR, Inc. ~ $15,000,000 Common
Stock ~ February 2005
SCOLR, Inc. is a biopharmaceutical
company leveraging proprietary, patented technologies in drug
delivery to introduce novel prescription drugs, OTC products and
dietary supplements. The Company is moving forward with human
clinicals for extended release formulations of Ibuprofen,
Pseudoephedrine and Raloxifene based on its proprietary CDT®
drug delivery platform. SCOLR turned to Taglich Brothers to
raise $15 million in a private placement of Common Stock with
institutional and accredited individual investors. This
additional capital allows the Company to continue is current
development plans, seek partnerships with pharmaceutical
companies and pursue additional research and development
projects to the Company’s advantage. Taglich Brothers' support
for SCOLR has grown with the Company and has aligned long-term
investors’ interests with that of the Company.
The information
contained herein does not constitute a solicitation of any order
to buy or sell any securities. The information provided herein may
be displayed and printed for your personal, noncommercial use
only. You may not reproduce, retransmit, distribute, disseminate,
sell, publish, broadcast or circulate the information to anyone,
without the express written consent of Taglich Brothers, Inc.
|
